Workflow
Model-Informed Drug Development
icon
Search documents
SLP's Q3 Earnings Top, Sales Up Y/Y, Stock Gains Despite Lowered View
ZACKS· 2025-07-15 14:20
Key Takeaways SLP's Q3 EPS rose 67% to $0.45 on 10% revenue growth, beating estimates on Pro-ficiency strength. Organic sales fell 4% as biosimulation softness and cautious client spending pressured growth. SLP slashed its 2025 revenue forecast by 15% due to delays, cancellations and weaker services.Simulations Plus, Inc. ((SLP) reported third-quarter fiscal 2025 adjusted earnings of 45 cents per share, which expanded 66.7% year over year. The figure also surpassed the Zacks Consensus Estimate of 26 cents ...
Certara Announces Expansion of Clinical Technology Collaboration with Merck
Globenewswire· 2025-07-08 12:00
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and qualityRADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agree ...
Certara (CERT) FY Earnings Call Presentation
2025-06-25 11:12
Certara William F. Feehery, Ph.D. Chief Executive Officer William Blair 25th Annual Growth Stock Conference Wednesday, June 4th, 2025 Disclaimer Numerical figures in the presentation have been subject to rounding adjustments. Acc ordingly , numeric al f igures shown as tota ls in various tables may not be arithmetic aggregations of the figures that precede them. Trademarks and Service Marks The Certara design logo, "Certara," and our other registered or common law trademarks, service marks or trade names ap ...
Certara(CERT) - 2024 Q4 - Earnings Call Transcript
2025-02-27 01:03
Certara, Inc. (NASDAQ:CERT) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc. Michael Cherny - Leerink Partners Christine Rains - William Blair David Windley - Jefferies Constantine Davides - Citizens Securities Andrew Moss - Bank of America Kyle Crews - UBS Operator Good day, and t ...